11 Most Profitable NASDAQ Stocks to Buy Now

6. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

TTM Net Income as of June 13: $4.49 billion

Forward P/E Ratio as of June 13: 14.27

Number of Hedge Fund Holders: 66

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 Revolutionizing Atopic Dermatitis/RAD Conference on June 7.

The DISCOVER trial enrolled 120 subjects with AD and Fitzpatrick skin types IV-VI (defined as light brown to black skin with high melanin content). Patients aged 12 years and older received Dupixent monotherapy every 2 weeks based on weight after a loading dose. At the 24-week mark, the study met its primary endpoint: 76% of participants achieved at least a 75% improvement in overall disease severity as measured by the Eczema Area and Severity Index (EASI-75).

Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was invented using Regeneron’s VelocImmune technology and developed in collaboration with Sanofi. It is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways without being an immunosuppressant. Over 1,000,000 patients are currently being treated with Dupixent globally.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. Sanofi (NASDAQ:SNY) is a healthcare company that researches, develops, manufactures, and markets therapeutic solutions.